CUSIP No. 221005 10 1 Page 1 of 5 Pages
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 2)[FN]1
Corvas International, Inc.
(Name of Issuer)
Common Stock, $.001 par value
(Title of Class of Securities)
221005 10 1
(CUSIP Number)
Jeremy L. Curnock Cook John C. MacMurray, Esq.
Rothschild Asset Management Ltd. Reboul, MacMurray, Hewitt,
Five Arrows House Maynard & Kristol
St. Swithin's Lane 45 Rockefeller Plaza
London EC4N 8NR England New York, New York 10111
Tel. 011-171-280-5000 Tel. (212) 841-5700
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
February 16, 2000
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d- 1(e), 13d-1(f) or 13d-1(g), check the following
box [ ].
- --------
1 The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page. The information required on
the remainder of this cover page shall not be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section of the Act but shall be subject to
all other provisions of the Act.
<PAGE>
CUSIP No. 221005 10 1 Page 2 of 5 Pages
1) Name of Reporting Person International
S.S. or I.R.S. Identification Biotechnology
No. of Above Person Trust plc
2) Check the Appropriate Box (a) [ ]
if a Member of a Group (b) [ ]
3) SEC Use Only
4) Source of Funds WC
5) Check if Disclosure of
Legal Proceedings is Not Applicable
Required Pursuant to
Items 2(d) or 2(e)
6) Citizenship or Place
of Organization United Kingdom
Number of 7) Sole Voting 2,175,837 shares of
Shares Beneficially Power Common Stock, $.001
Owned by par value ("Common
Reporting Person Stock")
8) Shared Voting
Power -0-
9) Sole Disposi- 2,175,837 shares of
tive Power Common Stock
10) Shared Dis-
positive Power -0-
11) Aggregate Amount Beneficially 2,175,837 shares of
Owned by Each Reporting Person Common Stock
12) Check if the Aggregate
Amount in Row (11)
Excludes Certain Shares
13) Percent of Class
Represented by 12.44%
Amount in Row (11)
14) Type of Reporting
Person CO
<PAGE>
CUSIP No. 221005 10 1 Page 3 of 5 Pages
Amendment No. 2 to Schedule 13D
Reference is hereby made to the statement on Schedule 13D originally
filed with the Securities and Exchange Commission on February 9, 1996, as
amended by Amendment No.1 thereto filed with the Securities and Exchange
Commission on September 24, 1999 (as amended, the "Schedule 13D"). Terms defined
in the Schedule 13D are used herein as so defined.
The Schedule 13D is hereby amended as follows:
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 is hereby amended by adding the following thereto:
This statement relates to the transactions by IBT in the shares of
Common Stock of the Issuer consummated by IBT from the period February 1, 2000
through March 1, 2000, including the exercise by IBT on February 9, 2000 of
warrants to purchase an aggregate 1,561,337 shares of Common Stock. The source
of funds for such exercise was IBT's working capital, or funds available for
investment.
Item 5. Interest in Securities of the Issuer.
Item 5 is hereby amended and restated to read in its entirety as
follows:
(a) Based on a total of 17,488,391 shares of Common Stock outstanding,
IBT owns 2,175,837 shares of Common Stock, or approximately 12.44% of the Common
Stock outstanding.
(b) Except as described in Item 6 of the Schedule 13D, IBT has sole
power to vote or direct the voting of and to dispose or to direct the
disposition of the shares of Common Stock referred to in paragraph (a) above.
(c) Except as set forth in Item 3 above and as set forth below,
neither IBT nor any of the persons identified in Item 2 above has effected any
transaction in the Common Stock in the past 60 days. In addition to the exercise
of the warrants, the following transactions were effected by IBT:
On February 14, 2000, IBT sold an aggregate 90,000 shares of Common
Stock on the open market at a per share price of $13.94.
On February 15, 2000, IBT sold an aggregate 30,000 shares of Common
Stock on the open market at a per share price of $14.75.
<PAGE>
CUSIP No. 221005 10 1 Page 4 of 5 Pages
On February 16, 2000, IBT sold an aggregate 95,000 shares of Common
Stock on the open market at a per share price of $14.85.
On February 17, 2000, IBT sold an aggregate 123,000 shares of Common
Stock on the open market at a per share price of $ 15.50.
On February 18, 2000, IBT sold an aggregate 119,500 shares of Common
Stock on the open market at a per share price of $15.98.
On February 22, 2000, IBT sold an aggregate 18,000 shares of Common
Stock on the open market at a per share price of $14.94.
On February 23, 2000, IBT sold an aggregate 20,000 shares of Common
Stock on the open market at a per share price of $13.70.
On February 24, 2000, IBT sold an aggregate 70,000 shares of Common
Stock on the open market at a per share price of $13.60.
On February 25, 2000, IBT sold an aggregate 30,000 shares of Common
Stock on the open market at a per share price of $14.29.
On February 28, 2000, IBT sold an aggregate 120,000 shares of Common
Stock on the open market at a per share price of $12.17.
On February 29, 2000, IBT sold an aggregate 120,000 shares of Common
Stock on the open market at a per share price of $12.30.
On March 1, 2000, IBT sold an aggregate 250,000 shares of Common Stock
on the open market at a per share price of $16.30.
(d) No other person has the power to direct the receipt of dividends
on, or the proceeds from sales of, the shares of Common Stock owned by IBT.
(e) Not applicable.
<PAGE>
CUSIP No. 221005 10 1 Page 5 of 5 Pages
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: March 8, 2000
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
By: /s/Jeremy L. Curnock Cook
Director
